News & partners

Dianosic is a biotech focused on the development of novel solutions integrated drug and
delivery system for the localized treatment of patients with chronic rhinitis and chronic rhinosinusitis.

Latest news

Tous Investissement Non classifié(e) Parteners Prix

Juil 10, 2023

Snitem – Dianosic reçoit le prix « coup de coeur » du public

Mar 31, 2021

Challenges – Dianosic a été sélectionnée parmi les 100 startups les plus innovantes où investir en 2021 !

Our investors

We built a solid network of partners to support company funding and growth.

Wiseed

Bpi France

Fondation Force

Eurométropole de Strasbourg

Banque Populaire Rives de Paris

Caisse d’épargne Grand Est

La Région Grand Est

Reinventing drug delivery via the intranasal route

Dianosic develops complex intranasal formulations and advanced drug-delivery solutions for chronic respiratory diseases and central nervous system disorders.

News & partners

Latest news

Snitem – Dianosic reçoit le prix « coup de coeur » du public

Challenges – Dianosic a été sélectionnée parmi les 100 startups les plus innovantes où investir en 2021 !

We built a solid network of partners to support company funding and growth.

Reinventing drug delivery via the intranasal route

Cutting-edge platform of intranasal, long-acting solid dosage forms

Significant potential across respiratory and neurological indications

Solving a critical adherence challenge

€7M raised in 2025 — led by Aptar Pharma

A complementary team